Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways

@article{Pugatsch2006AntierbB2TI,
  title={Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways},
  author={Thea Pugatsch and Suzan Abedat and Chaim Lotan and Ronen Beeri},
  journal={Breast Cancer Research},
  year={2006},
  volume={8},
  pages={R35 - R35}
}
Cardiac dysfunction is among the serious side effects of therapy with recombinant humanized anti-erbB2 monoclonal antibody. The antibody blocks ErbB-2, a receptor tyrosine kinase and co-receptor for other members of the ErbB and epidermal growth factor families, which is over-expressed on the surface of many malignant cells. ErbB-2 and its ligands neuregulin and ErbB-3/ErbB-4 are involved in survival and growth of cardiomyocytes in both postnatal and adult hearts, and therefore the drug may… CONTINUE READING
14 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

of Health: Guide for the Care and Use of Laboratory Animals (NIH Publication No

  • US National Institute
  • 85-23, revised
  • 1996
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…